Abstract
Background: TRPS-1 is a new GATA transcription factor that is differentially expressed in breast cancer (BC) where it been found recently to regulate epithelial-to-mesenchymal transition (EMT). Patients and methods: We carried out a quantitative immunohistochemistry (qIHC) analysis of TRPS-1 expression in 341 primary-stage I-III BC samples in relation to patient clinical characteristics as well as its prognostic value, especially in an estrogen receptor-positive (ER+) subgroup. Results: Higher TRPS-1 expression was significantly associated with a number of clinical and pathological characteristics as well as with improved overall survival (OS) and disease-free survival (DFS). Among stage I/II ER+ BC patients who received endocrine therapy alone, those with high TRPS-1 expression had significantly longer OS and DFS. There was also a strong association between TRPS-1 levels and the EMT marker E-cadherin in the ER+ invasive ductal carcinoma cases. Analysis of gene expression data on a panel of BC lines found that TRPS-1 expression was low or absent in BC lines having enriched mesenchymal features. Conclusions: Our data indicated that TRPS-1 is an independent prognostic marker in early-stage BC and a new EMT marker that can distinguish patients with ER+ BC who will respond longer to adjuvant endocrine therapy.
Original language | English (US) |
---|---|
Pages (from-to) | 2534-2542 |
Number of pages | 9 |
Journal | Annals of Oncology |
Volume | 24 |
Issue number | 10 |
DOIs | |
State | Published - Oct 2013 |
Keywords
- Breast cancer
- Immunohistochemistry
- Prognostic marker
- Trps-1
ASJC Scopus subject areas
- Hematology
- Oncology
MD Anderson CCSG core facilities
- Clinical Trials Office